Table 1. Demographic, echocardiographic data and circulating biomarkers of the rats in the in vivo study.

Parameters	Control group	HF group	FENO group
	(N = 6)	(N = 6)	(N = 6)
Body weight (g) 5 week/17 week	160.5 ± 0.5/280.3 ± 21.6	156.5 ± 1.5/331.7 ± 17.5*	158.5 ± 0.7/352.0 ± 16.5*
Heart weight (g)	0.76 ± 0.25	1.01 ± 0.10*	0.98 ± 0.11*
HW/BW (%)	0.27 ± 0.07	0.30 ± 0.02*	0.28 ± 0.03
Adiponectin (ng/mL)	3.36 ± 2.5	11.3 ± 7.8*	6.11 ± 5.5*, **
Baseline FS (%)	62 ± 3	59 ± 3	61 ± 2
FS at 12-week (%)	59 ± 3	52 ± 3*	57 ± 2

^*P < 0.05 vs. Control group;

^**P < 0.05 vs. HF group;

(N) is the number of animals used to calculate the mean ± S.E.M. of the presented data in Control group (normal control rats), HF group (rats received daunorubicin followed by treatment with vehicle), and FENO group (rats received daunorubicin followed by treatment with fenofibrate).

HF, heart failure; FENO, fenofibrate; HW, heart weight; BW, body weight; FS, fractional shortening